Clinical trials
Ovarian Cancer Metastatic Recurrent clinical trials
Below are recruiting ovarian cancer metastatic recurrent clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07782164Recruiting
Irreversible electroporation for recurrent pelvic tumors
This study tests a new technique called irreversible electroporation (IRE) for treating pelvic tumors that have returned despite earlier treatment. IRE uses electrical pulses to destroy cancer cells without surgery, offering a potential option when other local treatments like surgery or radiation are not suitable.
Amsterdam, North HollandAges 18 years+ - NCT06014190RecruitingPhase 2
HS-20089 for ovarian and endometrial cancer
This trial tests a new medication (HS-20089) for people with ovarian or endometrial cancer that has come back or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
Hefei, AnfeiAges 18 years+ - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Orlando, FloridaAges 18 years+ - NCT07718854RecruitingPhase 2
Study of two drugs for advanced ovarian clear cell cancer
This study tests two investigational drugs, alone or together, for advanced ovarian clear cell cancer that has not responded to usual treatments. The goal is to see if these drugs help shrink or control the cancer.
Boston, MassachusettsAges 18 years+ - NCT06660511RecruitingEarly Phase 1
Combination therapy for HER2-positive platinum-resistant ovarian cancer
This trial tests a combination of two drugs—Disitamab Vedotin and Anlotinib—for patients with ovarian cancer that has come back after platinum chemotherapy. It is designed for people whose tumors show a specific protein called HER2, and it aims to see if the combination is safe and effective.
Changsha, HunanAges 18 years+ - NCT07495384Recruiting
CapsuleX and cisplatin for platinum-resistant ovarian cancer
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Changchun, JilinAges 18 years+ - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Little Rock, ArkansasAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT07340164RecruitingPhase 2
Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Seoul, SeoulAges 18 years+ - NCT07311577RecruitingPhase 2
Trial of a drug combo for HER2-positive ovarian cancer
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
Nanjing, JiangsuAges 18–75 - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07024173RecruitingPhase 3
HRS-8080 versus doctor's choice for advanced breast cancer
This trial tests a new medicine called HRS-8080 for locally advanced or metastatic breast cancer. It compares HRS-8080 with whatever treatment your doctor would normally choose for you.
Guangzhou, GuangdongAges 18–75 - NCT06994195RecruitingPhase 3
Comparing an experimental drug to standard chemo for ovarian cancer
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06964009RecruitingPhase 1
New drug plus paclitaxel for resistant ovarian cancer
This trial tests a new drug called DT2216 combined with the chemotherapy drug paclitaxel for ovarian cancer that has stopped responding to platinum-based chemo. The goal is to see if this combination can shrink or slow the cancer, and to find a safe dose.
Boston, MassachusettsAges 18 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Orlando, FloridaAges 18 years+ - NCT06839144RecruitingPhase 2
Medications before surgery to slow ovarian cancer growth
This trial tests whether giving two common medications before and after surgery can slow the growth of ovarian cancer. The medications may help reduce stress signals that could make cancer spread faster during surgery.
Ramat GanAges 20–85 - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Birmingham, AlabamaAges 18 years+ - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Aurora, ColoradoAges 18 years+ - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT05113368RecruitingPhase 2
Regorafenib plus fulvestrant for recurrent low-grade ovarian cancer
This trial tests whether regorafenib (a targeted pill) plus fulvestrant (an injection that lowers estrogen signaling) can slow down recurrent low-grade serous ovarian cancer. It may help people whose cancer has returned after prior treatments.
Cleveland, OhioAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Little Rock, ArkansasAges 19 years+ - NCT06547840RecruitingPhase 1
Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
BristolAges 18 years+
Hear when a new Ovarian Cancer Metastatic Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ovarian cancer metastatic recurrent?
- Yes. Clin2 currently lists 95 recruiting ovarian cancer metastatic recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ovarian cancer metastatic recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ovarian cancer metastatic recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.